Comprehensive Genomic Profiling liquid biopsy trends in clinical trials

Comprehensive Genomic Profiling (CGP) allows biomedical laboratories to consolidate individual biomarkers into a single NGS assay. CGP testing started from minimal amounts of FFPE tissue and is now leveraging liquid biopsy to facilitate sample collection while decreasing the need for invasive tissue biopsy procedures.  

Choosing adequate panel content, combined with sophisticated bioinformatics solutions,  allows users to detect variants at very low variant allele frequencies, making the assay  compatible for biomarker development programs and clinical trial use.  

In this webcast, the speaker will help researchers to determine workflow and bioinformatics considerations when consolidating independent biomarkers into a panel that enables CGP from liquid biopsy samples in translational research.  

Discover:

• Factors contributing to the trend of CGP testing from liquid biopsy samples in clinical trials
• Workflow considerations before selecting a liquid biopsy CGP assay
• The impact of the bioinformatics solution used to detect low frequency variants to meet the needs of translational researchers

Robin Harrington, M.S.
Research Associate, Molecular Characterization Laboratory (MoCha)
Frederick National Laboratory for Cancer Research